Dergiler / Düşünen Adam - Psikiyatri ve Nörolojik Bilimler Dergisi / 2021 / Cilt: 34 - Sayı: 1

The severity of non-planning impulsivity and cannabis use problems in distinguishing patients with synthetic cannabinoid use disorder and cannabis use disorder

Sayfa
41–49
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: It was shown in our study that cases with SC use disorder had a higher risk of impulsivity and problematic substance use than those with cannabis use disorder, and the CUPIT-B and non-planning impulsiveness sub-scales were also predictors of SC use disorder.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: The present study aims to identify whether there is a difference between the synthetic cannabinoid (SC) and cannabis use disorder groups in terms of impulsivity and problems arising from substance use, as well as to determine the variables that distinguish SC use disorder cases from cannabis use disorder.
📊
Temel Bulgular & Veri:Method: Fifty-two male patients with SC and 45 male patients with cannabis use disorder who were admitted to the AMATEM clinic of Bakirkoy Mental and Neurological Diseases Training and Research Hospital were included in the study.
💡
Sonuç & Katkı:Conclusion: It was shown in our study that cases with SC use disorder had a higher risk of impulsivity and problematic substance use than those with cannabis use disorder, and the CUPIT-B and non-planning impulsiveness sub-scales were also predictors of SC use disorder.
🔬Tür:Uygulamalı Anket & Alan Araştırması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Objective: The present study aims to identify whether there is a difference between the synthetic cannabinoid (SC) and cannabis use disorder groups in terms of impulsivity and problems arising from substance use, as well as to determine the variables that distinguish SC use disorder cases from cannabis use disorder. Method: Fifty-two male patients with SC and 45 male patients with cannabis use disorder who were admitted to the AMATEM clinic of Bakirkoy Mental and Neurological Diseases Training and Research Hospital were included in the study. The participants were evaluated using the Barrat Impulsiveness Scale (BIS-11), Cannabis Use Problems Identification Test (CUPIT), Adult Cannabis Problems Questionnaire (CPQ), and Cannabis Withdrawal Scale (CWS). Results: The SC use disorder group had higher rates of unemployment, suicide, and self-mutilation than the cannabis use disorder group. The SC use disorder group scored significantly higher than those with cannabis use disorder in BIS-11, CUPIT, CPQ total score and sub-scale scores, and CWS score. Conclusion: It was shown in our study that cases with SC use disorder had a higher risk of impulsivity and problematic substance use than those with cannabis use disorder, and the CUPIT-B and non-planning impulsiveness sub-scales were also predictors of SC use disorder.

🔖

Bu Makaleye Atıf Yap

ÇENGEL, H. Y., BOZKURT, M., EVREN, C. (2021). The severity of non-planning impulsivity and cannabis use problems in distinguishing patients with synthetic cannabinoid use disorder and cannabis use disorder. Düşünen Adam - Psikiyatri ve Nörolojik Bilimler Dergisi, Cilt: 34 - Sayı: 1, 41–49. https://ajindex.com/articles/218441

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Hall WD, Lynskey M. Is cannabis a gateway drug? Testing hypotheses about the relationship between cannabis use and the use of other illicit drugs. Drug Alcohol Rev 2005; 24:39-48
  2. Copeland J, Pokorski I. Progress toward pharmacotherapies for cannabis-use disorder: an evidence-based review. Subst Abuse Rehabil 2016; 7:41-53
  3. Evren C, Yilmaz Cengel H, Bozkurt M, Evren B, Umut G, Agachanli R. Psychometric properties of the Turkish versions of the Cannabis Use Problems Identification Test (CUPIT) and the adult Cannabis Problems Questionnaire (CPQ). J Psychoactive Drugs 2017; 49:83-89
  4. Evren C, Bozkurt M. Synthetic cannabinoids: crisis of the decade. Dusunen Adam The Journal of Psychiatry and Neurological Sciences 2013; 26:1-11
  5. Dresen S, Ferreirós N, Pütz M, Westphal F, Zimmermann R, Auwärter V. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds. J Mass Spectrom 2010; 45:1186-1194
  6. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). New psychoactive substances in Europe: An update from the EU Early Warning System. https://www.emcdda.europa. eu/system/files/publications/65/TD0415135ENN.pdf. Accesed October 31, 2020
  7. Gurdal F, Asirdizer M, Aker RG, Korkut S, Gocer Y, Kucukibrahimoglu EE, et al. Review of detection frequency and type of synthetic cannabinoids in herbal compounds analyzed by Istanbul Narcotic Department of the Council of Forensic Medicine, Turkey. J Forensic Leg Med 2013; 20:667-672
  8. Schneir AB, Cullen J, Ly BT. “Spice” girls: synthetic cannabinoid intoxication. J Emerg Med 2011; 40:296-299
  9. Vardakou I, Pistos C, Spiliopoulou Ch. Spice drugs as a new trend: mode of action, identification and legislation. Toxicol Lett 2010; 197:157-162
  10. Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 2014; 144:12-41
  11. Demirakca T, Sartorius A, Ende G, Meyer N, Welzel H, Skopp G, et al. Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabidiol. Drug Alcohol Depend 2011; 114:242-245
  12. Hoyte CO, Jacob J, Monte AA, Al-Jumaan M, Bronstein AC, Heard KJ. A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Ann Emerg Med 2012; 60:435-438
  13. Perry JL, Carroll ME. The role of impulsive behavior in drug abuse. Psychopharmacology (Berl) 2008; 200:1